Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, has released its financial results for the second quarter ending June 30, 2025. The company reported a reduction in its loss from operations, which totaled approximately $6.8 million, compared to a loss of $11.9 million during the same period in 2024. Armata's grant and award revenue amounted to $2.2 million, attributed to the company's AP-SA02 program for S. aureus bacteremia, with no grant revenue recorded in the previous year's comparable quarter. Research and development expenses declined to approximately $6.4 million from $8.5 million in the prior year, while general and administrative expenses decreased to $2.6 million from $3.4 million. As of June 30, 2025, Armata held $4.3 million in unrestricted cash and cash equivalents, down from $9.3 million at the end of 2024. Significant developments include Armata's secured credit agreement with Innoviva Strategic Opportunities LLC for a $15 million loan maturing in 2029, intended to support the advancement of its lead therapeutic candidate, AP-SA02. The company also announced positive results from the Phase 1b/2a diSArm trial for AP-SA02, which met all primary endpoints for safety, tolerability, and clinical response. As of August 12, 2025, Armata had approximately 36.2 million common shares outstanding.